Skip to main content
. 2022 Jan 9;6(1):ytac004. doi: 10.1093/ehjcr/ytac004

Table 1.

Patient characteristics in comparison with previously published reports1,4

Case 1 Case 2 Rosner et al., 7 patients 1 Montgomery et al., 23 patients 4
Age (years) 23 20 Mean 27 Mean 25
Sex Male Male All male All male
Ethnicity White White 6 white, 1 Hispanic —
Vaccine type mRNA COVID-19 vaccine Moderna mRNA COVID-19 vaccine Moderna

  • 1 mRNA COVID-19 Vaccine Moderna

  • 5 BNT162b2-mRNA (Biontech/Pfizer)

  • 1 COVID-19 Vaccine Janssen® (Johnson & Johnson), single dose

  • 16 mRNA COVID-19 Vaccine Moderna

  • 7 BNT162b2-mRNA (Biontech/Pfizer)
Vaccine dose 2nd 2nd

  • 4 patients: 2nd

  • BNT162b2-mRNA (Biontech/Pfizer)

  • 1 patient: 2nd

  • mRNA COVID-19 Vaccine Moderna

  • 1 patient: 1st

  • BNT162b2-mRNA (Biontech/Pfizer)

  • 14 patients: 2nd

  • mRNA COVID-19 Vaccine Moderna

  • 6 patients: 2nd

  • BNT162b2-mRNA (Biontech/Pfizer)

  • 2 patients: 1st

  • mRNA COVID-19 Vaccine Moderna

  • 1 patient: 1st

  • BNT162b2-mRNA (Biontech/Pfizer)
Days to presentation 5 3 Mean 4 —
Days to symptom onset 1 1 — Mean 2
Prior COVID-19 infection 0 0 1 of 7 3 of 23

COVID-19, coronavirus disease 2019.